摘要
IgA肾病(IgAN)是世界范围内最常见的肾小球疾病,我国IgAN占原发性肾小球肾炎的45.2%～58.2%。IgAN目前发病机制尚不清楚,临床工作中血管紧张素转化酶抑制剂(ACEI)/血管紧张素Ⅱ受体拮抗剂(ARB)、糖皮质激素、免疫抑制剂等药物应用广泛,进行了很多有益探索,但治疗方案仍缺乏统一标准。2010年美国肾脏病学会年会(ASN)上,改善全球肾脏疾病预后组织(KDIGO)提出了有关IgAN循证治疗意见的初稿,本文就此循证治疗意见作一综述。
IgA nephropathy（IgAN） is the most common glomerulus disease in the world,and IgAN accounts for 45.2% to 58.2% of primary glomerulonephritis in China.The pathogenesis of IgAN remains unknown,and angiotensin converting enzyme inhibitor（ACEI）/angiotensin Ⅱ receptor blocker（ARB）,corticosteroid and immunosuppressive agents are widely used in clinics.However,there has been no unified standard in IgAN therapy.In 2010 Renal Week of American Society of Nephrology（ASN）,Kidney Disease Improving Global Outcomes（KDIGO） put forward suggestions on the treatment of IgAN based on evidence-based medicine.In this paper,these suggestions are reviewed.
出处
《上海交通大学学报（医学版）》
CAS
CSCD
北大核心
2012年第3期361-365,共5页
Journal of Shanghai Jiao tong University:Medical Science
